Generalized joint laxity at baseline does not affect fusion rate or clinical outcomes

Generalized joint laxity at baseline does not affect fusion rate or clinical outcomes

BY ADMIN /   WEDNESDAY, 16 DECEMBER 2015 /

According to findings in a recently published study, generalized joint laxity has little effect on fusion rates or the clinical outcomes of pain intensity and functional status, but it may have a negative effect on adjacent segment pathology after posterior lumbar interbody fusion.

Researchers conducted a retrospective comparative study that included 37 patients with generalized joint laxity (GJL) and 219 patients without GJL. The two groups were followed for 2 years after undergoing posterior lumbar interbody fusion (PLIF), with the researchers comparing fusion rates, low back pain intensity on a VAS and functional outcome based on the Oswestry Disability Index (ODI) between the two groups.

Two years after surgery, 91.9% of patients with GJL and 91.8% of patients without GJL experienced successful fusion, according to radiographic images in the study.

Both groups experienced significant decreases in VAS scores for low back pain, with improvements in pain intensity of 75.1% for the GJL group and 77.9% in the non-GJL group; however, the difference between the groups for low back pain, as well as the difference between the groups for ODI score, was not considered statistically significant, according to the researchers.

The researchers observed adjacent segment pathology to be present in both the superior and inferior segments within both groups, but this was also not considered to be significantly different between the two groups.

Patients in the GJL group were observed to have a greater degree of severe degeneration based on modified Pfirrmann classification compared with patients without GJL, which was considered a statistically significant difference, according to the researchers.

The researchers concluded that although GJL may contribute to the worsening or loosening of adjacent segment pathology, GJL at baseline does not affect fusion rates or clinical outcomes.

Integrity Life Sciences delivers a multitude of orthotic treatment options to address one of the most costly systemic ailments in the world, chronic low back and neck pain. Our advanced solution begins with the Integrity Spinal Care System (ISCS) ™ and its proprietary iELCiPS Technology™. The ISCS non-surgical spinal decompression modality systems are engineered to provide pain relief for compressive and degenerative conditions of the spine. Specifically, conditions that may be treated include: neck pain and back pain associated with herniated discs, protruding discs, degenerative disc disease, posterior facet syndrome, and sciatica. It achieves these effects through decompression of intervertebral discs, that is, unloading due to distraction and positioning.

As a compliment to the ISCS, Integrity offers the very effective Integrity Gel Support Brace™. Our advanced lumbar support brace is a fitting compliment to non-surgical spinal decompression therapy and was designed as an adjunct therapy for those suffering from back pain due to disc related conditions. The Integrity Gel Support Brace may be used with or without Integrity’s non-surgical spinal decompression systems and is an excellent treatment option for the patient to use at home.

In addition, Integrity Life Sciences has been exclusively granted the use of all of the technology, products, US Patent and Trademark Office’s assignments, logos and other forms of intellectual property that were created by Axiom Worldwide, INC under the leadership of Jim Gibson from Tampa, Florida. The agreement specifically includes the flagship product DRX 9000™, its family of products, and all of its derivatives such as the DRX9000C. Integrity offers support for these products, which includes: sales, maintenance services, and repairs. Only Integrity Life Sciences is Registered with the US FDA as a Factory Authorized – Contract Manufacturer – for Axiom Worldwide and the DRX9000 True Non-Surgical Spinal Decompression Systems™

James Gibson, President of Integrity Life Sciences and Axiom Worldwide states “Our partners, in over 50 countries and territories, have the unique opportunity to present a cutting edge medical device, utilizing a clinically validated protocol that restores a patient’s quality of life non-surgically and without pharmaceutical or invasive intervention“. With a body of published clinical research from around the world will support and strengthen your sales presentation; members of our medical advisory board herald from prestigious institutions such as Johns-Hopkins and The Mayo Clinic just to name a few. In addition, partners will have confidence in a quality product that adheres to the stringent standards mandated by FDA, CE, and ISO. Sales, marketing, and technical training is offered in prestigious locations in Europe, Asia, the Middle East and throughout the United States.

Learn more @: www.IntegrityLifeSciences.com or www.AxiomWorldwide.com

Integrity Life Sciences, LLC and Axiom Worldwide, INC are privately held companies with global interests and shareholders with international partners located across the globe with a mission of “Restoring Integrity to the Spine™” and delivering "True Non-Surgical Spinal Decompression"

For additional information please visit: www.IntegrityLifeSciences.com.

Elements as Published in: The Medical News